HR 4374

To amend the Federal Food, Drug, and Cosmetic Act to authorize additional emergency uses for medical products to reduce deaths and severity of injuries caused by agents of war, and for other purposes.

Congress: 115 (2017–2019, Ended)
Chamber: House
Policy Area: Health
Introduced: Nov 13, 2017
Current Status: Became Public Law No: 115-92.
Latest Action: Became Public Law No: 115-92. (Dec 12, 2017)
Law: 115-92 (Enacted Dec 12, 2017)
Official Text: https://www.congress.gov/bill/115th-congress/house-bill/4374

Sponsor

Name: Rep. Walden, Greg [R-OR-2]
Party: Republican • **State:** OR • **Chamber:** House

Cosponsors

No cosponsors are listed for this bill.

Committee Activity

Committee	Chamber	Activity	Date
Armed Services Committee	House	Referred to	Nov 14, 2017
Energy and Commerce Committee	House	Referred To	Nov 13, 2017

Subjects & Policy Tags

Policy Area:

Health

Related Bills

No related bills are listed.

Summary (as of Dec 12, 2017)

(This measure has not been amended since it was introduced. The expanded summary of the House passed version is repeated here.)

(Sec. 1) This bill amends the Federal Food, Drug, and Cosmetic Act to allow the Food and Drug Administration (FDA) to authorize the emergency use of an otherwise unapproved medical product if the Department of Defense (DOD) determines that there is a military emergency involving an agent that may cause imminently life-threatening and specific risk to U.S. forces. If a military emergency is determined to exist, the bill allows DOD to request that the FDA expedite certain procedures for approving medical products that would be reasonably likely to diagnose, prevent, treat, or mitigate such risk. The FDA must take specified actions to facilitate such a request by DOD.

The bill repeals provisions of the National Defense Authorization Act for Fiscal Year 2018 that allow DOD, rather than the FDA, to authorize the emergency use of an unapproved product under similar circumstances.

Unless DOD determines such meetings to be unnecessary, the FDA shall meet with DOD: (1) semi-annually to conduct a full review of relevant medical products in the DOD portfolio; and (2) quarterly to discuss the development status of regenerative medicine advanced therapy, blood, and vaccine medical products and projects that DOD prioritizes.

Actions Timeline

- **Dec 12, 2017:** Signed by President.
- **Dec 12, 2017:** Became Public Law No: 115-92.
- **Nov 30, 2017:** Presented to President.
- **Nov 16, 2017:** Passed/agreed to in Senate: Passed Senate without amendment by Unanimous Consent.(consideration: CR S7270)
- **Nov 16, 2017:** Passed Senate without amendment by Unanimous Consent. (consideration: CR S7270)
- **Nov 16, 2017:** Message on Senate action sent to the House.
- **Nov 15, 2017:** Mr. Walden moved to suspend the rules and pass the bill.
- **Nov 15, 2017:** Considered under suspension of the rules. (consideration: CR H9297-9300)
- **Nov 15, 2017:** DEBATE - The House proceeded with forty minutes of debate on H.R. 4374.
- **Nov 15, 2017:** Passed/agreed to in House: On motion to suspend the rules and pass the bill Agreed to by voice vote.(text: CR H9297-9298)
- **Nov 15, 2017:** On motion to suspend the rules and pass the bill Agreed to by voice vote. (text: CR H9297-9298)
- **Nov 15, 2017:** Motion to reconsider laid on the table Agreed to without objection.
- **Nov 15, 2017:** Received in the Senate, read twice.
- **Nov 14, 2017:** Referred to the Subcommittee on Military Personnel.
- **Nov 13, 2017:** Introduced in House
- **Nov 13, 2017:** Referred to the Committee on Energy and Commerce, and in addition to the Committee on Armed Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.